Literature DB >> 2296629

Methylazoxymethanol (MAM)-induced brain lesion and oral dyskinesia in rats.

P Johansson1.   

Abstract

The effects of methylazoxymethanol (MAM)-induced brain lesions on vacuous chewing movements (VCM) were examined in rats given chronic haloperidol treatment (0.1 or 1 mg/kg/day) for 18 months. At the end of the experiment striatal, pallidal, and nigral activities of glutamate decarboxylase (GAD) were measured. MAM-lesioned rats had an elevated rate of VCMs compared to unlesioned controls. This effect was stable during the whole 18-month experiment. In unlesioned control rats chronic haloperidol produced a gradual increase in VCM rates, but this effect was not further exacerbated in MAM-lesioned animals. After chronic haloperidol treatment with the higher dose (1 mg/kg/day) GAD activity was reduced in substantia nigra (-20%), globus pallidus (-35%), and striatum (-26%) of unlesioned rats. MAM caused a reduction of GAD activity in substantia nigra (-29%) and globus pallidus (-29%). Chronic haloperidol did not influence these effects of MAM-induced lesion. The present results show that a MAM-induced brain lesion, in contrast to cortical ablations, cannot be used to amplify the haloperidol-induced VCM increase or influence the nigral GAD activity in a rat model for tardive dyskinesia.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2296629     DOI: 10.1007/bf02245793

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  21 in total

1.  Effect of chronic neuroleptic or L-DOPA administration on GABA levels in the rat substantia nigra.

Authors:  K G Lloyd; O Hornykiewics
Journal:  Life Sci       Date:  1977-11-15       Impact factor: 5.037

2.  Changes in the activity of GAD in the basal ganglia of the rat after striatal dopaminergic denervation.

Authors:  J Segovia; M Garcia-Munoz
Journal:  Neuropharmacology       Date:  1987-09       Impact factor: 5.250

3.  Ontogeny of neurochemical markers for noradrenergic, GABAergic, and cholinergic neurons in neocortex lesioned with methylazoxymethanol acetate.

Authors:  M V Johnston; J T Coyle
Journal:  J Neurochem       Date:  1980-06       Impact factor: 5.372

4.  Drug holidays alter onset of oral movements in rats following chronic haloperidol.

Authors:  W W Sant; G Ellison
Journal:  Biol Psychiatry       Date:  1984-01       Impact factor: 13.382

5.  Histological and neurochemical effects of fetal treatment with methylazoxymethanol on rat neocortex in adulthood.

Authors:  M V Johnston; J T Coyle
Journal:  Brain Res       Date:  1979-07-06       Impact factor: 3.252

6.  Loss of intrinsic striatal neurons after methylazoxymethanol acetate treatment in pregnant rats.

Authors:  W Balduini; M P Abbracchio; G Lombardelli; F Cattabeni
Journal:  Brain Res       Date:  1984-07       Impact factor: 3.252

7.  Oral dyskinesia in rats following brain lesions and neuroleptic drug administration.

Authors:  L M Gunne; J Growdon; B Glaeser
Journal:  Psychopharmacology (Berl)       Date:  1982       Impact factor: 4.530

8.  Monoamine neurotransmitter metabolism in microencephalic rat brain after prenatal methylazoxymethanol treatment.

Authors:  H Hallman; G Jonsson
Journal:  Brain Res Bull       Date:  1984-09       Impact factor: 4.077

9.  Association with persistent neuroleptic-induced dyskinesia of regional changes in brain GABA synthesis.

Authors:  L M Gunne; J E Häggström; B Sjöquist
Journal:  Nature       Date:  1984 May 24-30       Impact factor: 49.962

10.  Oral dyskinesia in brain-damaged rats withdrawn from a neuroleptic: implication for models of tardive dyskinesia.

Authors:  R B Glassman; H N Glassman
Journal:  Psychopharmacology (Berl)       Date:  1980       Impact factor: 4.530

View more
  1 in total

1.  A neurobehavioral systems analysis of adult rats exposed to methylazoxymethanol acetate on E17: implications for the neuropathology of schizophrenia.

Authors:  Holly Moore; J David Jentsch; Mehdi Ghajarnia; Mark A Geyer; Anthony A Grace
Journal:  Biol Psychiatry       Date:  2006-04-11       Impact factor: 13.382

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.